AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 NOV 6 - (NewsRx.com & NewsRx.net) -- Circulating tumor DNA may not be a sufficiently accurate reflection of breast cancer clinical status or tumor activity.
"We evaluated the potential utility of occult circulating tumor DNA as a molecular marker of disease in subjects previously diagnosed with breast cancer. Using 24 microsatellite markers located at sites of frequent loss of heterozygosity (LOH) or allele imbalance in breast cancer, we analyzed DNA from 16 primary tumors (Stage IIA or more advanced) and 30 longitudinally collected plasma specimens," researchers in the United States report.
"Clinical data at the time of plasma collection were obtained. All 16 tumors were characterized by an individual pattern of LOH. LOH was detected in 12 of 30 (40%) plasma samples, taken from eight of 14 (57%) subjects. However, the number of LOH in plasma was small (n=15), and the mean proportion of LOH was much lower than in the tumors (.05 vs. 0.52)," wrote Q. Wang and colleagues, Boston University Medical Center.
"Although infrequent, 12 of 15 (80%) plasma LOH were concordant with abnormalities in the paired tumors, and the mean percent LOH was higher than in normal plasmas, suggesting that they were authentic tumor-derived abnormalities. We found, despite this, no association, between plasma LOH and tumor stage or clinical status at time of blood collection (i.e., LOH was as common in subjects with no evident disease as in those with evident disease)," the researchers wrote.
"In ...